Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00727597 · ClinicalTrials.gov registry record · Phase 3
A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT
A Phase 3 study, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 3
- Development phase
- 101
- Enrollment target
NCT00727597 is a Phase 3 study that has completed, run by Georgetown University. The registered enrollment target is 101 participants.
The verdict
NCT00727597, a Phase 3 study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 101 participants
- Enrollment target
Study Summary
The hope of this study is to gather data and information about the tolerability and effectiveness of Lexiva versus Sustiva in patients who have have been generally underrepresented in clinical trials.
Interventions
- DRUG Efavirenz 600mg
- DRUG Boosted Lexiva
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00727597
The ClinicalTrials.gov registry entry for NCT00727597 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Efavirenz 600mg is the first listed.
NCT00727597 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00727597 about?
NCT00727597 is a clinical study titled "A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT". The hope of this study is to gather data and information about the tolerability and effectiveness of Lexiva versus Sustiva in patients who have have been generally underrepresented in clinical trials.
What is the current status of trial NCT00727597?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 101 participants. The study started on 2008-07. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00727597?
The interventions under investigation include: Efavirenz 600mg (DRUG), Boosted Lexiva (DRUG).
Who is sponsoring clinical trial NCT00727597?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.